NCT02437422View on ClinicalTrials.gov

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 5, 2015

Primary Completion Date

November 18, 2015

Study Completion Date

November 18, 2015

Conditions
Renal Insufficiency, Chronic
Interventions
BIOLOGICAL

SANGUINATE

Single two-hour infusion of SANGUINATE

Trial Locations (1)

45267-0585

University of Cincinnati/ Division of Nephrology, Cincinnati

Sponsors
All Listed Sponsors
lead

Prolong Pharmaceuticals

INDUSTRY